Related Experiment Video
Updated: Feb 21, 2026

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
Published on: March 5, 2017
Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment
Mohamed Abou-El-Enein1, Toni Cathomen2, Zoltán Ivics3
1Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Abstract:
As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.
Related Concept Videos
CRISPR
What is Genetic Engineering?
CRISPR/Cas9 Genome Editing

